Compare
X4 Pharmaceuticals, Inc vs C4 Therapeutics, Inc. vs Precision Biosciences Inc vs Kymera Therapeutics, Inc.
| Latest fiscal year | X4 Pharmaceuticals, Inc XFOR | C4 Therapeutics, Inc. CCCC | Precision Biosciences Inc DTIL | Kymera Therapeutics, Inc. KYMR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $35.11M | $35.95M | $34.26M | $39.21M |
| Revenue growth (YoY) | n/m | +1.0% | -50.1% | -16.7% |
| Gross margin | 83.6% (computed) | n/a | n/a | 0.0% (computed) |
| Operating margin | -247.4% | -320.5% | -152.2% | -891.1% |
| Net margin | -225.6% | -292.1% | -133.4% | -794.0% |
| Net income | -$79.20M | -$104.99M | -$45.72M | -$311.35M |
| EPS (Diluted) | -$1.87 | -$1.27 | -$3.56 | -$3.69 |
| Operating cash flow | -$85.62M | -$98.69M | -$65.84M | -$232.89M |
| Free cash flow | -$85.62M | -$99.30M | -$65.93M | -$234.34M |
| Cash & equivalents | $217.05M | $74.60M | $110.82M | $357.01M |
| Total assets | $290.46M | $359.07M | $154.42M | $1.74B |
| Total liabilities | $104.17M | $102.49M | $62.17M | $163.15M |
| Shareholders' equity | $186.29M | $256.59M | $92.25M | $1.58B |
| Return on year-end equity | -42.5% | -40.9% | -49.6% | -19.7% |
| Shares outstanding | 90.91M | 96.91M | 24.09M | 81.32M |
Revenue, most recent five fiscal years
| Fiscal year | X4 Pharmaceuticals, Inc | C4 Therapeutics, Inc. | Precision Biosciences Inc | Kymera Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $35.11M Ended 2025-12-31 | $35.95M Ended 2025-12-31 | $34.26M Ended 2025-12-31 | $39.21M Ended 2025-12-31 |
| 1 year earlier | $2.56M Ended 2024-12-31 | $35.58M Ended 2024-12-31 | $68.70M Ended 2024-12-31 | $47.07M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $20.76M Ended 2023-12-31 | $48.73M Ended 2023-12-31 | $78.59M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $31.10M Ended 2022-12-31 | $25.10M Ended 2022-12-31 | $46.83M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $45.78M Ended 2021-12-31 | $115.53M Ended 2021-12-31 | $72.83M Ended 2021-12-31 |